NCT03233711 2026-03-18
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
6 trialsNCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT04534075 2025-09-08
FIDURA
Sahlgrenska University Hospital
Phase 3 Completed
NCT06207981 2025-09-02
KANALRAD
Federation Francophone de Cancerologie Digestive
Phase 3 Recruiting
NCT04635423 2025-08-11
V503-064
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06866574 2025-07-31
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
Xiamen University
Phase 3 Active not recruiting